New drug may help kids with kidney disease avoid relapses

NCT ID NCT07388810

Not yet recruiting Disease control Sponsor: Mao Jianhua Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether one or two doses of ripertamab can help children aged 16 and older who have frequent relapses or steroid-dependent nephrotic syndrome. The goal is to see which dose works better at preventing relapses and reducing the need for steroids. The trial will enroll 312 participants and follow them for one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ripertamab
What this could lead to: If successful, this could offer a more effective treatment option to reduce relapses and steroid use in children with nephrotic syndrome.
What could go wrong: This is an early-stage trial with no phase specified, so results may not confirm benefit. Risks include potential side effects from ripertamab and the steroid regimen.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates